Kenya Hagans and Nick Meza Author American Society for Pharmacy Law Article About Compounding Pharmacy Suing GLP‑1 Manufacturers
Kenya Hagans and Nick Meza, Quarles & Brady Health & Life Sciences attorneys, authored an article that was featured in an American Society for Pharmacy Law issue. The article discusses a compounding pharmacy filing a lawsuit against GLP‑1 drug makers, claiming they illegally restricted access to key ingredients and misled the public to limit competition.
An excerpt:
Strive claims that Lilly and Novo carried out this conduct through exclusive agreements with telehealth providers that include provisions prohibiting the prescribing of compounded products. Strive alleges that these agreements directly restrict patient access to compounded products, thereby unlawfully restricting competition in the GLP-1 marketings in the United States…
The complaint characterizes these compounded products as the only substitutes for Lill’s and Novo’s branded GLP-1 medications.5 The four GLP-1 branded medications with a prominent presence in the United States GLP-1 drug market include, as detailed in the complaint, Ozempic, Wegovy, Mounjaro, and Zepbound…